Xin Lang Cai Jing·2025-10-09 02:32Core Points - The stock price of Ailis dropped by 5.05% to 104.67 CNY per share, with a trading volume of 285 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 47.101 billion CNY [1] - Ailis is primarily engaged in the research, production, and sales of innovative drugs, with 99.93% of its revenue coming from drug sales [1] Fund Holdings - According to data, a fund under Guotai Haitong Asset Management holds a significant position in Ailis, specifically the Guotai Junan Innovative Medicine Mixed Fund A (014157), which reduced its holdings by 5,459 shares in the second quarter, now holding 89,500 shares, accounting for 5.53% of the fund's net value [2] - The fund has a total size of 1.07 billion CNY and has achieved a year-to-date return of 27%, ranking 3,866 out of 8,238 in its category [2] Fund Manager Performance - The fund manager of Guotai Junan Innovative Medicine Mixed Fund A is Li Zibo, who has been in the position for 3 years and 292 days, managing assets totaling 2.881 billion CNY [3] - During his tenure, the best fund return was 44.36%, while the worst return was 2.12% [3]